What Oftan Flurekain Treats: Main Uses and Benefits

Oftan Flurekain's therapeutic role is concentrated on managing two key areas of ophthalmic examination: procedural discomfort and diagnostic visibility.

The primary benefit plays a role in managing acute procedural pain and sensitivity of the eye surface. The solution is commonly used to help with short-term surface numbing of the cornea and conjunctiva, which contributes to improved comfort during essential contact assessments. This supports the patient during episodes of heightened discomfort, such as during intraocular pressure measurements (tonometry) or minor surgical acts like foreign body removal.

---

The solution is considered relevant in clinical settings marked by the symptomatic manifestation of structural surface damage to the eye. It is applied when clinicians need to locate and delineate specific conditions, which include corneal abrasions, ulcers, or epithelial defects linked to severe dry eye. By staining compromised areas, the solution supports diagnostic visibility, assisting the process of assessment of the damage, which supports the initiation of subsequent patient care.

---

Quick Fact: Relief for Procedural Discomfort
Symptom Category: Acute pain and sensitivity associated with clinical procedures.
Core Benefit: Provides supportive relief to help ease the overall symptom burden during necessary eye contact.
Patient Group: Relevant for individuals across all age groups undergoing short ocular diagnostics.

The official regulatory profile for Oftan Flurekain (or similar combinations) strictly defines the patient populations who are permitted, restricted, or prohibited from using the medicine for ophthalmic procedures.

Contraindicated Populations

Use is strictly prohibited (contraindicated) for patients with a known hypersensitivity to fluorescein sodium, oxybuprocaine, any formulation component, or any topical anaesthetics belonging to the p-aminobenzoic acid group. The medicine is also contraindicated if a patient has an existing eye infection.

Restricted and Conditional Use

Certain patient groups require special precaution based on regulatory labeling. This includes individuals with a history of systemic conditions such as cardiac diseases, hyperthyroidism, or hepatic diseases. Use on an inflamed or hyperaemic eye also requires caution. Contact lens wearers must remove their lenses prior to use, restricting use until the anaesthetic effect has fully subsided.

Age and Reproductive Status

The medicine’s use is established for diagnostic procedures in both adult and pediatric patients. However, for pregnant women, human data are insufficient; therefore, use is only permitted if clearly needed. Similarly, use during lactation requires caution as it is unknown if the active ingredient is excreted in human milk.

Interactions with other medicines and products

The official interaction profile for Oftan Flurekain is established through regulatory data documenting pharmacodynamic interference and mandatory formulation restrictions.

---

Pharmacodynamic Interaction Patterns

Interactions are linked to the Oxybuprocaine anaesthetic component, affecting the actions of co-administered medicines. Co-administration with the antimicrobial class Sulfonamides may result in a reduction of the expected antimicrobial effect. Anticholinesterases are documented to inhibit the metabolism of the anaesthetic, leading to a prolongation of the anaesthetic effects.

A further interaction exists with the neuromuscular blocking agent Suxamethonium (Succinylcholine), where the anaesthetic may competitively enhance its blocking action. These official statements establish constraints related to the efficacy and duration of co-administered medicines.

---

Interaction-Related Restrictions and Incompatibilities

The regulatory profile includes strict constraints related to product formulation and admixture. The local anaesthetic component is officially stated to be incompatible with Silver nitrate and Mercury salts. This constraint prohibits co-administration with these non-drug substances. The product is also documented as chemically incompatible with alkaline substances and eye drops containing Chlorhexidine acetate. No mandatory timing separation rules or clinically significant interactions with food, alcohol, or supplements are documented in the official prescribing information.

The mechanism of action for Oftan Flurekain is defined by the independent, functionally facilitated actions of its two components, Oxybuprocaine and Fluorescein sodium.

Modulation of Peripheral Nociceptive Signaling

Oxybuprocaine operates as a reversible sodium channel blocker, engaging the voltage-gated sodium channels (Nav) in sensory nerve membranes of the cornea and conjunctiva. By binding to the channel pore, the molecule prevents the influx of sodium ions required for cell depolarization. This inhibition causes a failure in the action potential cascade, resulting in a targeted suppression of the nociceptive signaling pathway and a subsequent suppression of localized sensory neural function.

Optical Enhancement of Epithelial Integrity

Fluorescein sodium acts via a physical, non-pharmacodynamic mechanism. The hydrophilic dye selectively adheres to the exposed corneal stroma in areas lacking the protective epithelial cell layer. When excited by blue light, the dye undergoes fluorescence (light absorption followed by green light emission). This action provides an intense optical contrast, demonstrating defects in superficial tissue integrity.

Functional Facilitation

Both mechanisms exhibit functional facilitation: the anaesthetic component arrests the conduction of afferent nerve impulses, allowing the dye component's visualization mechanism to operate effectively under stable physiological conditions.

Official Administration Guidelines

The administration of this ophthalmic solution, which is generally a combination of fluorescein sodium (a disclosing agent) and oxybuprocaine hydrochloride (a local anesthetic), is governed by strict protocols for professional use only. This medicine is not intended for patient self-administration or home use.

Administration Scope	Detail
Route of Administration	Topical Ocular (Instilled into the eye)
Dosing Schedule	Instill 1 to 2 drops topically in the eye as needed to achieve adequate procedural anesthesia or for diagnostic purposes.
Preparation	Hands must be washed thoroughly prior to administration. The dropper tip must not touch the eye or any surface to maintain sterility.
Age-Group Rules	Dosing for pediatric patients must be determined by the prescribing professional.

Procedural Steps and Conditions

Official Procedural Steps: The medicine is applied by gently pulling down the lower eyelid to create a small pocket and instilling the prescribed number of drops. The eye should be closed gently after application.

Special Conditions: Soft contact lenses must be removed before using the drops and should only be reinserted after a waiting period, typically at least 15 minutes. Patients are instructed not to touch the eye for approximately 20 minutes following administration to prevent accidental injury due to the anesthetic effect. This topical anesthetic is for specific diagnostic or minor surgical procedures and is typically used on an as-needed basis.

Research Evidence / Overview of Studies for Oftan Flurekain

Evidence for Use in Ocular Diagnostic Procedures

This section summarizes the clinical and observational research that was studied for the product's role in assessments that require temporary numbing and improving visibility.

Research has focused on the combination of a temporary numbing agent (Oxybuprocaine) and a diagnostic dye (Fluorescein sodium). The combination was evaluated in studies that measured the successful completion of the required diagnostic procedure. Studies explored the use of both components in a single drop during assessments that require temporary numbing. Evidence derived from settings where tonometry was observed in studies described pressure readings that were highly correlated with those obtained using similar preparations. This research describes the patterns observed in the studies related to diagnostic assessment. Findings describe patterns where the onset of the numbing action was often observed within a minute of application.

Evidence for Detecting Corneal Epithelial Defects

This part details the research base supporting the use of the Fluorescein dye component during the visualization of breaks or damage to the corneal surface.

The use of Fluorescein sodium was studied during evaluations where the dye visibly stained areas of the eye. Studies monitored the use of the dye in the visualization of various epithelial conditions, such as scratches or ulcers, under a specialized cobalt blue filter. Evidence describes the use of the dye component, which is supported by extensive published literature and clinical practice. Research provides insight into the clarity and contrast observed when the dye is used to visualize structural surface damage. Since the dye is a standard tool in this diagnostic context, traditional randomized trials comparing it to an inactive substance are limited; the existing research often consists of observational data and regulatory reviews that confirm its long-standing diagnostic use.

Evidence for Short-Term Procedural Pain Control

This segment reviews the studies, including controlled and comparative trials, that have been conducted to evaluate the time course and degree of the numbing effect provided by the Oxybuprocaine component during minor surgical acts or high-contact clinical assessments.

Research examined the functional outcomes related to physical discomfort, specifically the suppression and recovery of corneal sensation. Studies monitored the time to onset of the numbing effect; an onset time within 30 seconds was observed in some reports. Comparative trials were used to evaluate this anaesthetic against others. The research contributes to understanding the temporary nature of the numbing action, which aligns with the short observation periods of procedures.

Key Studies & References

1. Effect of Oxybuprocaine Eye Drops on Corneal Volume and Thickness Measurements: A Systematic Review and Meta-analysis

Common questions about Oftan Flurekain (FAQ)

---

Q: How quickly should I feel the effects of Oftan Flurekain?

Research and official information indicate that the onset of the numbing effect has been observed within 30 seconds to 1 minute following the application of the drops. This rapid effect facilitates necessary diagnostic assessments by quickly suppressing localized sensation.

---

Q: What is the typical duration of use described for Oftan Flurekain?

Oftan Flurekain is a procedural diagnostic agent used on an as-needed basis for short examinations. The numbing effect from a single administration is temporary, typically lasting for approximately 10 to 20 minutes.

---

Q: Are there any common long-term side effects reported for Oftan Flurekain?

Regulatory warnings caution that this medicine is for short-term, procedural use. The potential for corneal epithelial toxicity, which may progress to permanent corneal damage, has been documented in association with prolonged or repeated use of this class of anesthetic.

---

Q: Can Oftan Flurekain affect driving ability?

The official side effect profile lists transient blurring of vision immediately following application. Due to this temporary visual disturbance, the ability to safely drive or operate machinery may be affected for a short period.

---

Q: Why is Oftan Flurekain only available by prescription?

The product is restricted to professional use due to the presence of a strong topical anesthetic component. The restriction is based on the documented regulatory concern regarding the risk of accidental eye injury or potential for misuse, which may lead to serious corneal damage.

---

Q: Can Oftan Flurekain be used for all types of eye infections?

No. According to the official contraindications, the use of this medicine is strictly prohibited if a patient has an existing eye infection. It is classified as a diagnostic aid and a local anesthetic, not as a therapeutic treatment for infections.

---

Q: What happens if I miss a use of Oftan Flurekain?

Since it is administered on an as-needed basis for specific procedures, the concept of a 'missed use' is not applicable as it is not a scheduled therapeutic treatment.

---

Q: Is Oftan Flurekain considered a steroid eye drop?

No. The official classification of Oftan Flurekain is a Topical Local Anaesthetic and an Ophthalmic Diagnostic Agent. It does not contain any corticosteroids.

---

Q: Is it true that Oftan Flurekain can affect blood sugar levels?

Official prescribing information does not contain documentation linking the use of Oftan Flurekain eye drops to changes in blood sugar levels.

---

Q: Does Oftan Flurekain have a black box warning?

The product itself does not have a Black Box Warning. This warning is typically reserved for certain systemic medications requiring the highest level of regulatory caution.

---

Q: Can Oftan Flurekain be used if I am taking oral antibiotics?

The official interaction profile identifies a potential reduction in the effect of the antibiotic class known as Sulfonamides if co-administered with this medicine. The official prescribing information does not list specific warnings or documented interactions for other broad classes of oral antibiotics.

---

Q: Does Oftan Flurekain have any known drug interactions with common pain relievers?

Official drug interaction information for this medicine does not document any clinically significant interactions with common pain relievers, food, alcohol, or dietary supplements.

---

Q: Does the use of alcohol affect Oftan Flurekain?

The official prescribing information does not document any clinically significant interaction or effect between the use of alcohol and Oftan Flurekain.

---

Q: Why do official documents mention 'risk of corneal perforation' with drugs like Oftan Flurekain?

Regulatory warnings associated with this class of anesthetic caution that prolonged use or misuse can lead to corneal epithelial toxicity. This condition is a form of serious corneal damage.

---

Q: Is Oftan Flurekain the same as other fluconazole eye drops? / What is the difference between Oftan Flurekain and just fluconazole drops?

No, Oftan Flurekain is a distinct medicine. It is a combination of Oxybuprocaine (an anesthetic) and Fluorescein sodium (a diagnostic dye). Fluconazole is a completely different active ingredient used as an antifungal medicine.

---

Q: Can using Oftan Flurekain affect the results of an eye exam?

The medicine is intended to facilitate diagnostic procedures; however, the temporary numbing and blurring effects could temporarily affect the results of other non-target exams, such as standard visual acuity testing or refraction.

---

Q: Is there a generic version of Oftan Flurekain available?

Oftan Flurekain is a brand name. The active ingredients, Oxybuprocaine and Fluorescein, are commonly used and widely available globally in various generic combination products for ophthalmic procedures.

---

Q: Does Oftan Flurekain contain preservatives?

Ophthalmic solutions often contain preservatives, such as benzalkonium chloride, to maintain sterility after opening. The specific composition, including the presence of any preservatives, is detailed in the official package leaflet.

---

Q: Can elderly patients use Oftan Flurekain without special precautions?

Official regulatory documents state that the medicine's use is established for both adult and pediatric patients. No additional precautions specific to the general elderly population are explicitly documented in primary safety materials.

---

Q: What has clinical research indicated about the expected time for symptoms to improve?

Oftan Flurekain is classified as a diagnostic agent and local anesthetic used to facilitate procedures. It is not a therapeutic medicine intended to treat a condition or disease, so there is no expected time for symptoms to 'improve' after its use.

Oftan Flurekain must be stored and handled according to the specific instructions provided in the regulatory labeling to ensure product stability.

Official Storage Conditions

Item	Requirement
Un-opened Temperature	Refrigerated (2 C to 8 C)
Light Protection	Store in the outer carton to protect from light
Opened Shelf-Life	28 days (when stored below 25 C)
Prohibited	Do not freeze

Handling and Disposal

The medicine must be stored out of the sight and reach of children. The product must not be used beyond the expiration date. Disposal must follow local regulations; the medicine must not be thrown into the sewer or household waste. Consult a pharmacist for proper disposal of the unused product.